NeuroOne to Present its Game-Changing Neuroscientific Technology at the Oppenheimer 32nd Annual Healthcare Conference and 34th Annual ROTH Conference

EDEN PRAIRIE, Minn., March 3, 2022 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it is scheduled to attend two investor conferences during the month of March 2022.

During the conferences, NeuroOne Chief Executive Officer Dave Rosa will discuss the Company’s high-definition, minimally invasive thin-film Evo® Cortical Electrodes for the diagnosis of various neurological conditions. Leveraging its game-changing technology developed in collaboration with Mayo Clinic, NeuroOne’s upcoming commercial and development catalysts include the Evo® sEEG diagnostic line (if cleared by the FDA) and further development of a combination diagnostic and ablation electrode system, as well as the potential for technology adaptation and entry into artificial intelligence and machine learning markets.

About NeuroOne® Medical Technologies Corporation

NeuroOne is a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. These solutions include electrodes that have the potential to reduce the number of hospitalizations, surgical procedures and cost while improving patient outcomes due to their potential for offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. A combination recording and RF ablation technology is currently under development. In addition, NeuroOne recently announced initial results of testing of its electrodes for long term recording and stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning. Visit n1mtc.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding clinical and pre-clinical testing, NeuroOne’s business strategy, regulatory clearance, market size and potential growth. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our technology will not perform as expected based on results of our pre-clinical testing; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; risks that we may not receive certain regulatory clearances; risks that we may not have accurately estimated the size and growth potential of the markets for our technology; and other risks and uncertainties related to market and other conditions, the impact of general economic, industry or political conditions in the United States or internationally and those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of the podcast and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-game-changing-neuroscientific-technology-at-the-oppenheimer-32nd-annual-healthcare-conference-and-34th-annual-roth-conference-301494042.html

SOURCE NeuroOne Medical Technologies Corporation